Prkdc participates in mitochondrial genome maintenance and prevents adriamycin-induced nephropathy in mice

Journal of Clinical Investigation

Volumn 120, Issue 11, 2010, Pages 4055-4064

  Papeta, Natalia ^a   Zheng, Zongyu ^a   Schon, Eric A ^a   Brosel, Sonja ^a   Altintas, Mehmet M ^b   Nasr, Samih H ^a   Reiser, Jochen ^b   D'Agati, Vivette D ^a   Gharavi, Ali G ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MITOCHONDRIAL DNA;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DNA DAMAGE; GENE; GENE EXPRESSION; GENE MAPPING; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOME; KIDNEY DISEASE; MITOCHONDRION; MOUSE; NONHUMAN; PODOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PRKDC GENE; SOUTHERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELLS, CULTURED; DNA MUTATIONAL ANALYSIS; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; DOXORUBICIN; GENETIC PREDISPOSITION TO DISEASE; GENOME, MITOCHONDRIAL; HUMANS; KIDNEY; KIDNEY DISEASES; MEMBRANE PROTEINS; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEAR PROTEINS; SEQUENCE ALIGNMENT;

EID: 78049418710     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI43721     Document Type: Article

References (60)

1. Rossmann P, Matousovic K, Bohdanecka M. Experimental adriamycin nephropathy. Fine structure, morphometry, glomerular polyanion, and cell membrane antigens. J Pathol. 1993;169(1):99-108.
2. Wang Y, Wang YP, Tay YC, Harris DC. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int. 2000;58(4):1797-1804.
3. Kaplan BS, Renaud L, Drummond KN. Effects of aminonucleoside, daunomycin, and adriamycin on carbon oxidation by glomeruli. Lab Invest. 1976;34(2):174-178.
4. Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med. 2006;354(13):1387-1401.
5. Kim YH, et al. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int. 2001;60(3):957-968.
6. Wharram BL, et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol. 2005;16(10):2941-2952.
7. Wiggins JE, et al. Podocyte hypertrophy, "adaptation," and "decompensation" associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction. J Am Soc Nephrol. 2005;16(10):2953-2966.
8. Bertani T, et al. Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events. Lab Invest. 1982;46(1):16-23.
9. Cao Q, et al. IL-10/TGF-{beta}-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis. J Am Soc Nephrol. 2010;21(6):933-942.
10. Cheng H, Fan X, Guan Y, Moeckel GW, Zent R, Harris RC. Distinct roles for basal and induced COX-2 in podocyte injury. J Am Soc Nephrol. 2009;20(9):1953-1962.
11. Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB, Liu Y. Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol. 2009;20(9):1997-2008.
12. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol. 1998;25(4 suppl 10):72-85.
13. Fukuda F, Kitada M, Horie T, Awazu S. Evaluation of adriamycin-induced lipid peroxidation. Biochem Pharmacol. 1992;44(4):755-760.
14. Paczek L, Teschner M, Schaefer RM, Kovar J, Romen W, Heidland A. Intraglomerular proteinase activity in adriamycin-induced nephropathy. Nephron. 1992;60(1):81-86.
15. Coers W, Huitema S, van der Horst ML, Weening JJ. Puromycin aminonucleoside and adriamycin disturb cytoskeletal and extracellular matrix protein organization, but not protein synthesis of cultured glomerular epithelial cells. Exp Nephrol. 1994;2(1):40-50.
16. Akman SA, Doroshow JH, Burke TG, Dizdaroglu M. DNA base modifications induced in isolated human chromatin by NADH dehydrogenase-catalyzed reduction of doxorubicin. Biochemistry. 1992;31(13):3500-3506.
17. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984;226(4673):466- 468.
18. Lawrence JW, Darkin-Rattray S, Xie F, Neims AH, Rowe TC. 4-Quinolones cause a selective loss of mitochondrial DNA from mouse L1210 leukemia cells. J Cell Biochem. 1993;51(2):165-174.
19. Adachi K, et al. A deletion of mitochondrial DNA in murine doxorubicin-induced cardiotoxicity. Biochem Biophys Res Commun. 1993;195(2):945-951.
20. Lebrecht D, Kokkori A, Ketelsen UP, Setzer B, Walker UA. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol. 2005;207(4):436-444.
21. Suliman HB, Carraway MS, Ali AS, Reynolds CM, Welty-Wolf KE, Piantadosi CA. The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy. J Clin Invest. 2007;117(12):3730- 3741.
22. Gross NJ, Getz GS, Rabinowitz M. Apparent turnover of mitochondrial deoxyribonucleic acid and mitochondrial phospholipids in the tissues of the rat. J Biol Chem. 1969;244(6):1552-1562.
23. Palmeira CM, Serrano J, Kuehl DW, Wallace KB. Preferential oxidation of cardiac mitochondrial DNA following acute intoxication with doxorubicin. Biochim Biophys Acta. 1997;1321(2):101-106.
24. Cannino G, Di Liegro CM, Rinaldi AM. Nuclear-mitochondrial interaction. Mitochondrion. 2007;7(6):359-366.
25. Scarpulla RC. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev. 2008;88(2):611-638.
26. Spinazzola A, et al. MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. Nat Genet. 2006;38(5):570-575.
27. Bourdon A, et al. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet. 2007;39(6):776-780.
28. Rahman S, Poulton J. Diagnosis of mitochondrial DNA depletion syndromes. Arch Dis Child. 2009;94(1):3-5.
29. Kimura T, Takeda S, Sagiya Y, Gotoh M, Nakamura Y, Arakawa H. Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet. 2003;34(4):440-445.
30. Viscomi C, et al. Early-onset liver mtDNA depletion and late-onset proteinuric nephropathy in Mpv17 knockout mice. Hum Mol Genet. 2009;18(1):12-26.
31. Zheng Z, et al. A Mendelian locus on chromosome 16 determines susceptibility to doxorubicin nephropathy in the mouse. Proc Natl Acad Sci U S A. 2005;102(7):2502-2507.
32. Zheng Z, Pavlidis P, Chua S, D'Agati VD, Gharavi AG. An ancestral haplotype defines susceptibility to doxorubicin nephropathy in the laboratory mouse. J Am Soc Nephrol. 2006;17(7):1796-1800.
33. Mott R. A haplotype map for the laboratory mouse. Nat Genet. 2007;39(9):1054-1056.
34. Dip R, Naegeli H. More than just strand breaks: the recognition of structural DNA discontinuities by DNA-dependent protein kinase catalytic subunit. FASEB J. 2005;19(7):704-715.
35. Staub E, Fiziev P, Rosenthal A, Hinzmann B. Insights into the evolution of the nucleolus by an analysis of its protein domain repertoire. Bioessays. 2004;26(5):567-581.
36. Blunt T, et al. Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation. Cell. 1995;80(5):813-823.
37. Kurimasa A, et al. Catalytic subunit of DNA-dependent protein kinase: impact on lymphocyte development and tumorigenesis. Proc Natl Acad Sci U S A. 1999;96(4):1403-1408. (Pubitemid 29098463)
38. Araki R, et al. Nonsense mutation at Tyr-4046 in the DNA-dependent protein kinase catalytic subunit of severe combined immune deficiency mice. Proc Natl Acad Sci U S A. 1997;94(6):2438-2443.
39. O'Bryan T, Weiher H, Rennke HG, Kren S, Hostetter TH. Course of renal injury in the Mpv17-deficient transgenic mouse. J Am Soc Nephrol. 2000;11(6):1067-1074.
40. Jhappan C, Morse HC 3rd, Fleischmann RD, Gottesman MM, Merlino G. DNA-PKcs: a T-cell tumour suppressor encoded at the mouse scid locus. Nat Genet. 1997;17(4):483-486.
41. O'Driscoll M, Jeggo PA. The role of double-strand break repair - insights from human genetics. Nat Rev Genet. 2006;7(1):45-54.
42. Franco S, Murphy MM, Li G, Borjeson T, Boboila C, Alt FW. DNA-PKcs and Artemis function in the end-joining phase of immunoglobulin heavy chain class switch recombination. J Exp Med. 2008;205(3):557-564.
43. Burma S, et al. DNA-dependent protein kinasein-dependent activation of p53 in response to DNA damage. J Biol Chem. 1999;274(24):17139-17143.
44. d'Adda di Fagagna F, et al. Effects of DNA nonhomologous end-joining factors on telomere length and chromosomal stability in mammalian cells. Curr Biol. 2001;11(15):1192-1196.
45. Ju BG, et al. A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science. 2006;312(5781):1798-1802.
46. Wong RH, Chang I, Hudak CS, Hyun S, Kwan HY, Sul HS. A role of DNA-PK for the metabolic gene regulation in response to insulin. Cell. 2009;136(6):1056-1072.
47. Jackson S, Gottlieb T, Hartley K. Phosphorylation of transcription factor Sp1 by the DNA-dependent protein kinase. Adv Second Messenger Phosphoprotein Res. 1993;28:279-286.
48. Hossain MB, Ji P, Anish R, Jacobson RH, Takada S. Poly(ADP-ribose) Polymerase 1 Interacts with Nuclear Respiratory Factor 1 (NRF-1) and Plays a Role in NRF-1 Transcriptional Regulation. J Biol Chem. 2009;284(13):8621-8632.
49. Nock A, et al. Identification of DNA-dependent protein kinase as a cofactor for the forkhead transcription factor FoxA2. J Biol Chem. 2009;284(30):19915-19926.
50. Woodard RL, Anderson MG, Dynan WS. Nuclear extracts lacking DNA-dependent protein kinase are deficient in multiple round transcription. J Biol Chem. 1999;274(1):478-485.
51. Ashley N, Poulton J. Anticancer DNA intercalators cause p53-dependent mitochondrial DNA nucleoid re-modelling. Oncogene. 2009;28(44):3880-3891.
52. Xia L, Jaafar L, Cashikar A, Flores-Rozas H. Identification of genes required for protection from doxorubicin by a genome-wide screen in Saccharomyces cerevisiae. Cancer Res. 2007;67(23):11411-11418.
53. Kaplan JM, et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet. 2000;24(3):251-256.
54. Winn MP, et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science. 2005;308(5729):1801-1804.
55. Brown EJ, et al. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet. 2010;42(1):72-76.
56. Rotig A, Munnich A. Genetic features of mitochondrial respiratory chain disorders. J Am Soc Nephrol. 2003;14(12):2995-3007. (Pubitemid 37509278)
57. Yamagata K, et al. Mitochondrial DNA mutations in focal segmental glomerulosclerosis lesions. J Am Soc Nephrol. 2002;13(7):1816-1823.
58. Eaton JS, Lin ZP, Sartorelli AC, Bonawitz ND, Shadel GS. Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis. J Clin Invest. 2007;117(9):2723-2734.
59. Mori C, Takanami T, Higashitani A. Maintenance of mitochondrial DNA by the Caenorhabditis elegans ATR checkpoint protein ATL-1. Genetics. 2008;180(1):681-686.
60. Chang L, et al. ATM-mediated serine 72 phosphorylation stabilizes ribonucleotide reductase small subunit p53R2 protein against MDM2 to DNA damage. Proc Natl Acad Sci U S A. 2008;105(47):18519-18524.